Screener Summaries Updates Institutions Sign In More Updates › Other Events › HELP Other Events · Jul 21, 2026
Helus Pharma (Nasdaq: HELP) announced the completion of enrollment for its APPROACH Phase 3 pivotal study of HLP003 in… HELP Helus Pharma Inc.
Helus Pharma (Nasdaq: HELP) announced the completion of enrollment for its APPROACH Phase 3 pivotal study of HLP003 in patients with Major Depressive Disorder (MDD). The study, which enrolled 223 participants, is on track to release topline data in the fourth quarter of 2026. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.
More from Helus Pharma Inc. Cybin Inc., operating commercially as Helus Pharma, announced the appointment of Regina Donohue as Chief People… Aug 18, 2026 Cybin Inc., doing business as Helus Pharma, filed interim financial statements for the three months ended June 30, 2026 Aug 14, 2026 Cybin Inc. announced the appointment of Michael Halstead as Chief Executive Officer, effective August 3, 2026 Aug 3, 2026 Cybin Inc. (d/b/a Helus Pharma) closed an underwritten offering of 10,309,280 common shares at US$4.85 per share… Jul 16, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
